Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. News about CMPX often centers on its antibody pipeline, clinical trial progress, financing activities, and corporate developments, reflecting its focus on angiogenesis, immune modulation, and tumor growth.
Investors and observers following Compass Therapeutics news can expect regular updates on key product candidates such as tovecimig, CTX-8371, CTX-10726, and CTX-471. The company issues press releases on milestones in the COMPANION-002 Phase 2/3 study of tovecimig in advanced biliary tract cancer, monotherapy data in metastatic colorectal cancer, and cohort expansions or new responses in the Phase 1 study of CTX-8371 in indications like non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma. Preclinical data releases for CTX-10726, including presentations at scientific meetings, also feature prominently.
Compass Therapeutics news coverage additionally includes quarterly financial results, cash and marketable securities updates, and descriptions of anticipated cash runway, as disclosed in earnings press releases and related Form 8-K filings. The company also announces public offerings of common stock and pre-funded warrants, with details on intended use of proceeds for research, clinical development, and preparations for potential commercialization.
Another recurring theme in CMPX news is participation in healthcare and biopharma investor conferences, where Compass presents its pipeline and corporate strategy. Press releases list appearances at events hosted by firms such as J.P. Morgan, Piper Sandler, Evercore, Guggenheim, Stifel, Cantor, and others. Leadership appointments, including additions to the senior management team, are also communicated through Globe Newswire releases.
This news page aggregates these company-issued updates and related coverage, offering a centralized view of clinical, scientific, financial, and corporate developments for Compass Therapeutics and its CMPX stock.
Compass Therapeutics, Inc. (OTC:CMPX) announced that data from its Phase 1 study of CTX-009, a bispecific antibody targeting DLL4 and VEGF-A, has been selected for oral presentation at the AACR-NCI-EORTC conference from October 7-10, 2021. The presentation will highlight safety, tolerability, and clinical activity data in patients with anti-VEGF-resistant solid tumors. CTX-009 has shown partial responses in heavily pre-treated patients and is currently advancing to Phase 1b and Phase 2 combination studies.
Compass Therapeutics, Inc. (OTC:CMPX), a clinical-stage biotechnology firm, announced that CEO Thomas Schuetz will participate in a fireside chat at the Citi 16th Annual Biopharma Conference on September 8, 2021, at 3:15 PM ET. The event will be accessible via the company’s website post-presentation. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics targeting oncology, particularly through understanding angiogenesis and the immune system. Founded in 2014 and headquartered in Boston, the company aims to enhance anti-tumor responses through innovative therapies.
Compass Therapeutics (OTCQB: CMPX) has announced a definitive merger agreement with TRIGR Therapeutics, a private oncology firm. Compass will acquire TRIGR through a stock-for-stock transaction, approved unanimously by both companies' boards. At the center of the deal is CTX-009, a bispecific antibody that targets DLL4 and VEGF-A, currently in Phase 1b trials. The acquisition will enhance Compass' pipeline, and TRIGR's management will join Compass' board. Closing is anticipated in Q2 2021, with considerations including 10,265,154 shares issued to TRIGR shareholders.
Compass Therapeutics (CMPX) reported its 2020 financial results, highlighting a net loss of $29.5 million, a decrease from $34.7 million in 2019. The company successfully completed a $60.5 million private placement, enabling its transition to a public entity and OTCQB listing. Clinical progress includes the Phase 1b expansion of the CTX-471 study, showing promising anti-tumor activity, with data expected in the second half of 2021. Cash and cash equivalents stood at $47.1 million, providing operational runway until Q2 2022.
Compass Therapeutics, Inc. (OTCQB: CMPX) announced the participation of CEO Thomas Schuetz in two virtual investor conferences: the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021, and the 33rd Annual Roth Conference on March 15-17, 2021. The H.C. Wainwright presentation will be available on demand, while a live panel discussion on bispecific antibodies will occur on March 16, 2021. Compass Therapeutics is focused on developing proprietary antibody therapeutics targeting solid tumors and hematological malignancies, including its lead candidate, CTX-471, in a Phase 1b study.
Compass Therapeutics, Inc. (OTCQB: CMPX) has announced that its common stock shares have been approved for trading on the OTCQB Venture Market in the U.S., effective March 5, 2021. The company specializes in developing proprietary antibody therapeutics aimed at treating solid tumors and hematological malignancies. Its lead candidate, CTX-471, is currently in a Phase 1 clinical study targeting patients who have relapsed after PD-1/PD-L1 treatment. The company operates from Boston, MA, and focuses on engaging the immune system through its innovative platforms.